Abstract
Clinical investigations were performed on cefotetan (CTT, YM09330), a new β-lactam antibiotic.
Cefotetan was administered to total 13 cases of respiratory tract infections (11 cases of pneumonia and 2 cases of lung abscess), at a daily dose of 2 g for 11 days (one case), 12 days (one case), 14 days (9 cases), 21 days (one case) and 25 days (one case).
Clinical response of cefotetan was excellent in 8 cases, good in 4 cases and fair in one case.
Side effects with cefotetan were observed in 2 cases consisting of skin eruption, drug induced fever and the elevation of serum transaminase.
